Last reviewed · How we verify
NCT03908333
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
Phase 1, PHASE2 trial testing Ascorbic Acid in Metastatic Pancreatic Cancer. Withdrawn.
1 May 2022
Quick facts
| Lead sponsor | Medical College of Wisconsin |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 May 2019 |
| Primary completion | 1 May 2022 |
| Estimated completion | 1 May 2023 |
| Sites | 6 locations across United States |
Drugs / interventions tested
- Ascorbic Acid (ASCORBIC ACID) — full drug profile →
- Paclitaxel protein-bound
- Cisplatin (cisplatin) — full drug profile →
- Gemcitabine (gemcitabine) — full drug profile →
Conditions studied
- Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
- Pancreas Cancer — all drugs for Pancreas Cancer →
- Pancreatic Adenocarcinoma Resectable — all drugs for Pancreatic Adenocarcinoma Resectable →
Sponsor
Medical College of Wisconsin
Who can join
18 and older, any sex, with Metastatic Pancreatic Cancer or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be given by intravenous (IV) infusion (through a vein into the bloodstream) or orally (taken by mouth). When taken by intravenous infusion, vitamin C can reach much higher levels in the blood than when the same amount is taken by mouth. Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The therapeutic potential of vitamins A, C, and D in pancreatic cancer.
Piotrowsky A, Burkard M, Schmieder H, Venturelli S, et al · · 2025 · PMID 39850424 · DOI 10.1016/j.heliyon.2024.e41598
Verify or expand the search:
- PubMed search for NCT03908333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ascorbic Acid
Trials testing the same drug.
- NCT03066115 — Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation · Phase 1 · withdrawn
- NCT04138394 — VItamin C in Thermal injuRY: The VICToRY Trial · Phase 3 · suspended
- NCT04354428 — Treatment for COVID-19 in High-Risk Adult Outpatients · Phase 2, PHASE3 · terminated
- NCT04342728 — Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation · NA · completed
- NCT04328961 — Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) · Phase 2, PHASE3 · completed
Other recruiting trials for Metastatic Pancreatic Cancer
Currently open trials in the same condition.
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
- NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
- NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
- NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting
Other Medical College of Wisconsin trials
Trials by the same sponsor.
- NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
- NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
- NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
- NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
- NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03908333 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
- Last refreshed: 30 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03908333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing